Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
about
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancerIs time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
P2860
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Statistical considerations and ...... ed non-small-cell lung cancer?
@en
type
label
Statistical considerations and ...... ed non-small-cell lung cancer?
@en
prefLabel
Statistical considerations and ...... ed non-small-cell lung cancer?
@en
P2093
P2860
P1476
Statistical considerations and ...... ed non-small-cell lung cancer?
@en
P2093
Christian Manegold
Gerald Schmid-Bindert
Lothar R Pilz
P2860
P356
10.3978/J.ISSN.2218-6751.2011.12.08
P577
2012-03-01T00:00:00Z